雷公藤治疗实验性重症肌无力大鼠的相关性研究

Correlation research about the expect of Tripterygium wilfordii in rats with experimental myasthenia gravis affect

目的探讨雷公藤治疗实验性重症肌无力大鼠的临床效果及其作用机理。方法以含有大鼠来源的抗自身乙酰胆碱受体AChRα97-116、完全弗氏佐剂(CFA)免疫健康的Lewis大鼠,建立实验性重症肌无力(EAMG)动物模型,将实验动物分为完全弗氏佐剂对照组(CFA组)、实验性重症肌无力模型组(EAMG组)和雷公藤治疗组(TWP组)3组,每组10只。依据Lennon评分法及体质量监测,初步评定雷公藤多甙对EAMG大鼠的治疗作用;应用免疫组织化学法检测各组大鼠胸腺和脾脏中白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、白细胞介素-17(IL-17)、γ干扰素(IFN-γ)阳性细胞分布情况;应用酶联免疫吸附试验方法(ELISA)检测大鼠血清中IL-4、IL-6、IL-17、IFN-γ的含量。结果 EAMG组大鼠体质量下降明显,Lennon评分逐周升高;TWP组大鼠发病时间迟缓,症状减轻,Lennon评分低于EAMG组,体质量高于EAMG组。ELISA检测示:与EAMG组比较,TWP组和CFA组大鼠血清中IL-17、IFN-γ表达量明显降低,而IL-4和IL-6表达量明显增高,差异有统计学意义(P<0.05);与EAMG组比较,TWP组大鼠胸腺和脾中IL-17表达水平明显降低;而IL-6和IL-4的表达量明显增高。结论雷公藤治疗实验性重症肌无力大鼠是通过改变CD4+T细胞各种亚群的比例来达到一定的治疗效果。

Objective mental myasthenia To explore clinical effect and mechanism of application triptolide treatment in experi gravis rats. Methods The Polypeptide fragments containing the rat sources AChRα97 116, complete Freundts adjuvant （CFA） were employed to induce Lewis rats to establish EAMG model. The rats were divided into three groups, CFA control group, Tripterygium glycosides （TG） treatment group, EAMG model group, and each had10 rats. According to Lennon score and weight monitoring, the therapeutic effect of Tripterygium glycosides were preliminary assessed by the Lennon scoring and body weight monitoring on EAMG rats. The distributions of IL- 4, IL-6, IL-17, IFN-γ-positive ceLLs were studied by immunohistochemistry in the thymus and spleen, contents of the serum IL-4, IL-6, IL-17, IFN-γ, respectively were detected by enzyme-Linked immunosorbent assay （ELISA）. Results In EAMGmodel group： the body weight of rats decreased significantly, and the Lennon scores increased by week. The expression levels of serum IL-17, IFN-γ, in the TWP treatment group and CFA groups were signifi- cantly reduced, while that of IL-6 and IL-4 were significantly higher, compared with the EAMG model group, the expressions of IL-17 were significantly reduced in thymus of TG treatment group, IL-6 and IL-4 were significantly higher, compared with the EAMG model group. Conclusion It was confirmed that ther- apeutic significance of triptolide treatment to experimental myasthenia gravis by altering various CD4＋T cell subsets in proportion.